Ann: 2023 Appendix 4G and Corporate Governance Statement, page-6

Yup. I'd spitball AT1 sp. is a good indication of a couple of things.

1. Lumos fluffed approval first time round. To me, something smells about FebriDx. I'm not convinced the FDA like how their product presumes to work. If this is true, practitioners will get the waft in their noses.
2. Marketing approval doesn't mean endorsement. But approval will always lead to a (relatively) big spike - even if short term (see CUV).
3. If there is a smell about the product, LDX will have an uphill battle with market penetration - at least to start with
4. If 3 is right, AT1 is not sitting on a near-term gold mine. A toll manufacturer is taking pennies in the $. It might tak some time for those pennies to be worth much